Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.47 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13648372 | 0.93 | DDR2 (0.52) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL5565332 | 0.92 | DDR2 (0.58) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL14453628 | 0.90 | RET (0.66) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL171181 | 0.88 | DDR2 (0.64) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL13648447 | 0.87 | DDR2 (0.51) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL170965 | 0.85 | DDR2 (0.73) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL14453630 | 0.84 | DDR2 (0.74) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL5564918 | 0.84 | DDR2 (0.59) | RETDDR2FLT3CSF1RKDR | |
| SCHEMBL171249 | 0.82 | DDR2 (0.66) | DDR2FLT3CSF1RKDRMAPK14 | |
| SCHEMBL5569082 | 0.82 | RET (0.62) | RETDDR2FLT3CSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007519653-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | claimed |
| EP-1730111-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-12-13 | — | — | EP | claimed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| EP-1730111-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | RET 40/4885DDR2 3546/4885FLT3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.